These analyses were restricted to patients with ERα positive breast cancer, where high tumor co-expression of progranulin and sortilin demonstrated a significantly worse BCSS compared to mixed groups (p=0.005, n=279) (Fig. 3a) similar to all samples described above. The gene discussed is GRN; the disease is breast carcinoma.